Your comment isn't all that relevant as Turing did NOT spend 'millions of thousands of dollars and a team of lawyers to get drugs approved'. Daraprim is a gener

Your comment isn't all that relevant as Turing did NOT spend 'millions of thousands of dollars and a team of lawyers to get drugs approved'. Daraprim is a generic which had been available for over 60 years. There were no R&D costs in this case. Instead, Turing was the sole provider of Daraprim. It switched to a closed distribution model so other generic manufacturers couldn't show equivalence, which is needed for FDA approval, then jacked up the price. At least, that's my understanding. In any case, it's far from what you suggest is the case.